These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25521405)

  • 21. Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
    Pan JB; Hou YH; Zhang GJ
    Asian Pac J Cancer Prev; 2013; 14(2):695-700. PubMed ID: 23621221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
    Drpa G; Sreter KB; Manojlovic S; Kukulj S
    Anticancer Drugs; 2018 Mar; 29(3):281-285. PubMed ID: 29280916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
    Carney BJ; Rangachari D; VanderLaan PA; Gowen K; Schrock AB; Ali SM; Costa DB
    Lung Cancer; 2017 Dec; 114():108-110. PubMed ID: 28870636
    [No Abstract]   [Full Text] [Related]  

  • 24. Targeted therapy: an evolving world of lung cancer.
    Lam KC; Mok TS
    Respirology; 2011 Jan; 16(1):13-21. PubMed ID: 20723139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib.
    Yan G; Yao R; Tang D; Qiu T; Shen Y; Jiao W; Ge N; Xuan Y; Wang Y
    Med Oncol; 2014 Oct; 31(10):203. PubMed ID: 25192889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Assessing the usefulness of erlotinib in patients with unknown or negative epidermal growth factor receptor mutation status].
    Ema T; Kawano R; Enomoto Y
    Gan To Kagaku Ryoho; 2013 Oct; 40(10):1377-80. PubMed ID: 24196074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.
    Venugopalan A; Lee MJ; Niu G; Medina-Echeverz J; Tomita Y; Lizak MJ; Cultraro CM; Simpson RM; Chen X; Trepel JB; Guha U
    Oncotarget; 2016 Aug; 7(34):54137-54156. PubMed ID: 27494838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
    Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
    Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy.
    Ahmed ZA; Moatter T; Siddiqui A; Pervez S
    Asian Pac J Cancer Prev; 2014; 15(17):7125-8. PubMed ID: 25227801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
    Kristiansen C; Olsen KE; Hansen NC; Hansen KH; Hansen O
    Acta Oncol; 2012 Sep; 51(7):948-9. PubMed ID: 22471746
    [No Abstract]   [Full Text] [Related]  

  • 32. [A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].
    Tanaka H; Okamoto T; Shinyama M; Matsumura S; Fujii T
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):1067-9. PubMed ID: 23986053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.
    Yu HA; Tian SK; Drilon AE; Borsu L; Riely GJ; Arcila ME; Ladanyi M
    JAMA Oncol; 2015 Oct; 1(7):982-4. PubMed ID: 26181354
    [No Abstract]   [Full Text] [Related]  

  • 34. [A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].
    Chen WQ; Li P; Wang Q; Zhang YJ; Li HY; Jin XT; Yan S; Kou GF; Cai SL; Liu G
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):133-137. PubMed ID: 29502374
    [No Abstract]   [Full Text] [Related]  

  • 35. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE; Ramalingam SS
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract]   [Full Text] [Related]  

  • 36. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
    Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
    Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
    Kalra N; Ashai A; Xi L; Zhang J; Avital I; Raffeld M; Hassan R
    Oncol Rep; 2012 Jun; 27(6):1794-800. PubMed ID: 22426987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalized medicine and inhibition of EGFR signaling in lung cancer.
    Gazdar AF
    N Engl J Med; 2009 Sep; 361(10):1018-20. PubMed ID: 19692681
    [No Abstract]   [Full Text] [Related]  

  • 39. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
    Dillon B; Naidoo B; Knight H; Clark P
    Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
    Tseng JS; Wang CL; Huang MS; Chen CY; Chang CY; Yang TY; Tsai CR; Chen KC; Hsu KH; Tsai MH; Yu SL; Su KY; Wu CW; Yang CT; Chen YM; Chang GC
    PLoS One; 2014; 9(9):e107160. PubMed ID: 25215536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.